메뉴 건너뛰기
.. 내서재 .. 알림
소속 기관/학교 인증
인증하면 논문, 학술자료 등을  무료로 열람할 수 있어요.
한국대학교, 누리자동차, 시립도서관 등 나의 기관을 확인해보세요
(국내 대학 90% 이상 구독 중)
로그인 회원가입 고객센터 ENG
주제분류

추천
검색

논문 기본 정보

자료유형
학술저널
저자정보
Heo Haejeong (Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Kim Jong-Hwan (Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Lim Hyun Jung (Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Kim Jeong-Hwan (Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Kim Miso (Seoul National University Hospital) Koh Jaemoon (Seoul National University College of Medicine) Im Joo-Young (Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Kim Bo-Kyung (Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Won Misun (Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Park Ji-Hwan (Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Shin Yang-Ji (Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Yun Mi Ran (Yonsei University College of Medicine) Cho Byoung Chul (Yonsei University College of Medicine) Kim Yong Sung (Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Kim Seon-Young (Korea Research Institute of Bioscience and Biotechnology (KRIBB)) Kim Mirang (Korea Research Institute of Bioscience and Biotechnology (KRIBB))
저널정보
대한생화학·분자생물학회 Experimental and Molecular Medicine Experimental and Molecular Medicine 제54권
발행연도
2022.8
수록면
1 - 14 (14page)
DOI
10.1038/s12276-022-00836-7

이용수

표지
📌
연구주제
📖
연구배경
🔬
연구방법
🏆
연구결과
AI에게 요청하기
추천
검색

초록· 키워드

오류제보하기
Acquired resistance to inhibitors of anaplastic lymphoma kinase (ALK) is a major clinical challenge for ALK fusion-positive non-small-cell lung cancer (NSCLC). In the absence of secondary ALK mutations, epigenetic reprogramming is one of the main mechanisms of drug resistance, as it leads to phenotype switching that occurs during the epithelial-to-mesenchymal transition (EMT). Although drug-induced epigenetic reprogramming is believed to alter the sensitivity of cancer cells to anticancer treatments, there is still much to learn about overcoming drug resistance. In this study, we used an in vitro model of ceritinib-resistant NSCLC and employed genome-wide DNA methylation analysis in combination with single-cell (sc) RNA-seq to identify cytidine deaminase (CDA), a pyrimidine salvage pathway enzyme, as a candidate drug target. CDA was hypomethylated and upregulated in ceritinib-resistant cells. CDA-overexpressing cells were rarely but definitively detected in the naïve cell population by scRNA-seq, and their abundance was increased in the acquired-resistance population. Knockdown of CDA had antiproliferative effects on resistant cells and reversed the EMT phenotype. Treatment with epigenome-related nucleosides such as 5-formyl-2′-deoxycytidine selectively ablated CDA-overexpressing resistant cells via accumulation of DNA damage. Collectively, our data suggest that targeting CDA metabolism using epigenome-related nucleosides represents a potential new therapeutic strategy for overcoming ALK inhibitor resistance in NSCLC.

목차

등록된 정보가 없습니다.

참고문헌 (0)

참고문헌 신청

함께 읽어보면 좋을 논문

논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!

이 논문의 저자 정보

최근 본 자료

전체보기

댓글(0)

0